Person

John Miles

Partner

BSc, PhD, Fellow of the Chartered Institute of Patent Attorneys, European Patent Attorney.
Partner in the Biotechnology & Pharmaceuticals group since 1999.

John completed his first degree at the University of Bristol where he was awarded the W E Garner prize for biochemistry in his final year, and undertook his doctoral studies in microbial molecular biology at Sheffield University.

John started his patent career in 1992 at Potter Clarkson, and since then has worked extensively with technology transfer organisations, spin-outs, SMEs and big pharma in securing, defending and opposing patent rights in a range of biotechnological and medical areas as part of their commercial strategies. He has particular expertise in the patenting of cancer-related genes and their uses, vaccines, biotherapeutics including antibodies, immunotherapies, siRNA molecules, biomarkers, industrial enzymes and their uses, DNA analytical methods, stem cell isolation and characterization, medical diagnostics and treatment regimes. John has advised several clients in respect of patent strategy and due diligence for their initial public offering of shares, as well as in relation to private funding rounds, and has helped develop creative patenting and licensing strategies to maximize value in a client's patent portfolio. He has acted in respect of entitlement disputes before the UK Patent Office, and has a significant opposition practice at the EPO having handled over 60 cases largely in the above fields.

In addition to his patent work, John is very well known for his expertise in supplementary protection certificates (SPCs). He has been responsible for coordinating the filing and prosecution of over 200 SPC applications around Europe, and is one of very few people who has taken two SPC cases to the Court of Justice of the European Union (namely Yissum and Georgetown University et al). He has also lectured and published extensively on the subject and contributes the chapter on SPCs to the European Patents Handbook.

Before joining Potter Clarkson, John was a lecturer in biochemistry and molecular biology at Glasgow University, and before that he did post-doctoral research work on mammalian cytochrome P450 genes for Cancer Research UK at Edinburgh University. During his research career, John authored over forty research and review papers for international journals in the fields of biochemistry, molecular biology and genetics, including Nature. While doing his post-doc, John co-invented a P450 pharamacogenetic test, and had the unusual distinction when he joined Potter Clarkson of being able to prosecute the patent to the invention to grant, and successfully defend oppositions to it at the EPO!

During his time at Potter Clarkson, John has held various management positions including training partner and he served on the Board of Management from 2006 to 2010.

DateNews Infomation
May
11
2012
Will Supplementary Protection Certificates soon become much more widely available?

On 3 May 2012, Advocate-General Verica Trstenjak delivered her opinion in the Neurim Pharmaceuticals case (C-130/11) that is pending before the Court of Justice of the EU (CJEU).

The opinion delivered by A-G Trstenjak is non-binding but will be taken into consideration by the CJEU when it reaches its final decision later this year. If confirmed by the CJEU, the conclusions would have a profound, liberalising effect on SPC practice in Europe for new medicinal products that contain previously authorised active ingredients.

SPCs

Supplementary Protection Certificates (SPCs) are national rights in Europe that protect authorised uses of a "product" (an active ingredient or a combination of actives) that has been subject to patent protection. The protection provided by SPCs is particularly valuable, as it can provide an effective barrier to generic competition for up to five (or even five and a half) years beyond patent expiry.

Mar
09
2012
VALUE ADDED SPCs - CJEU CLARIFIES BROAD SCOPE OF PROTECTION

Following hot on the heels of important SPC decisions issued in late 2011, the Court of Justice of the European Union (CJEU) has now issued a reasoned order in the Novartis v Actavis case (C-442/11).

Jan
24
2012
Supplementary Protection Certificates: The CJEU issues it's decision in two seminal cases

On 24 November 2011, the Court of Justice of the European Union issued decisions in two cases that have important and far-reaching consequences for the application of the law relating to the Supplementary Protection Certificates (‘SPCs')

Jan
06
2012
SUPPLEMENTARY PROTECTION CERTIFICATES: SOME FURTHER TWISTS

On 25 November 2011, the Court of Justice of the European Union (CJEU) decided three cases relating to Supplementary Protection Certificates (SPCs) by reasoned order (i.e. without a hearing). The orders follow judgements already handed down in the Medeva (C-322/10) and Georgetown University et al (C-422/10) cases that we previously reported in our IP Update No. 165. The following are further points of note.

Dec
09
2011
SUPPLEMENTARY PROTECTION CERTIFICATES: THE COURT OF JUSTICE AGREES WITH POTTER CLARKSON THAT SPCs WITH NEGATIVE TERMS ARE ACCEPTABLE

The Court of Justice of the European Union (CJEU) ruled yesterday in an important case (C-125/10, Merck Sharp & Dohme Corp. v Deutsches Patent- und Markenamt), relating to Supplementary Protection Certificates (SPCs). The decision of the CJEU is binding upon all national patent offices and courts, and dictates how the term of an SPC is calculated, especially in view of a 6-month extension of term that may be available.

In essence, the CJEU has approved "Model A" of an article published on 7 July 2007 by Mike Snodin and John Miles of this firm, which introduced the revolutionary concept of zero and negative term SPCs.

That is, the CJEU has decided that SPCs can be granted even if they initially have a zero or negative term, i.e. if less than 5 years and 1 day has elapsed between patent filing and Marketing Authorisation (MA) issuance. This is because, provided that at least 4 years, 6 months and 1 day has elapsed from between patent filing and MA issuance, a zero or negative term SPC can serve as the basis for an extended SPC with a positive term.

The particular factual background to this case is discussed in our IP Update no. 153 (relating to the opinion of the Advocate-General that has effectively been confirmed by the Court). However, the essential points of the case, as well as possible actions that you may wish to take, are outlined below.

Nov
24
2011
SUPPLEMENTARY PROTECTION CERTIFICATES: THE CJEU ISSUES ITS DECISION IN TWO SEMINAL CASES

On 24 November 2011, the Court of Justice of the European Union (CJEU) delivered its judgement in two seminal cases relating to Supplementary Protection Certificates (SPCs). Potter Clarkson represented Georgetown University, University of Rochester and Loyola University of Chicago in one case and the party in the other case was Medeva. Our IP Update No 155 discusses the corresponding Advocate General's opinion, which opinion is superseded by the present judgement. The ruling provides significant clarity and is binding on all EU national patent offices and courts.

Oct
27
2011
Further recognition as a leading firm by Chambers UK 2012

The newly available results for Chambers UK 2012 list Potter Clarkson LLP as a leading firm of Patent & Trade Mark Attorneys. As well as achieving band 1 status, which is the highest recommendation possible, four of the firm's Partners were also mentioned as key individuals.

Oct
10
2011
Might you be entitled to a longer SPC term?

Mike Snodin, a member of our SPC & Regulatory group, has published an article in the journal Scrip Regulatory Affairs that challenges the manner in which many patent offices in Europe calculate the terms of Supplementary Protection Certificates (SPCs) that are based upon a centralised (European Commission / European Medicines Agency) marketing authorisation.